Biogen

Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
Clinical Trials Arena
Fri, 01/10/25 - 11:18 am
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Alzheon
Private Medicare plans must cover Biogen's ALS drug, US agency says
Yahoo/Reuters
Thu, 12/12/24 - 11:45 pm
CMS
Medicare
Biogen
ALS
Qalsody
How a Biogen drug set the stage for a new biotech targeting ALS
BioPharma Dive
Sun, 11/17/24 - 09:27 pm
Biogen
Trace Neuroscience
Qalsody
ALS
Eisai wins over European regulators on Alzheimer’s drug Leqembi
BioPharma Dive
Thu, 11/14/24 - 10:28 pm
Eisai
Biogen
Leqembi
Alzheimer's disease
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
BioSpace
Thu, 11/14/24 - 11:19 am
Biogen
Leqembi
Qalsody
Skyclary
Zurzuvae
Spinraza
Eisai Cuts Fiscal 2024 Guidance for Biogen-Partnered Leqembi as Sales Disappoint Analysts
BioSpace
Sun, 11/10/24 - 09:27 pm
Eisai
Biogen
Leqembi
earnings
Alzheimer's disease
Eisai, Biogen eye 2025 approval for Leqembi autoinjector
Pharmaphorum
Fri, 11/1/24 - 10:57 am
Eisai
Biogen
Leqembi
Alzheimer's disease
FDA
Big Pharma earnings hang hope on the next generation of blockbusters
Pharma Voice
Thu, 10/31/24 - 09:19 am
Pfizer
JNJ
Biogen
Novartis
earnings
Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B
Fierce Biotech
Wed, 10/30/24 - 08:45 pm
Biogen
Neomorph
molecular glue
protein degradation
Biogen, Sage admit a defeat in major depression
BioPharma Dive
Wed, 10/30/24 - 08:43 pm
Biogen
SAGE Therapeutics
Zurzuvae
postpartum depression
major depressive disorder
Biogen C-suite shuffle: CFO retires and chief medical officer joins
Medical Marketing and Media
Tue, 10/29/24 - 08:02 pm
Biogen
executives
Biogen shows its IgAN hand with felzartamab data
Pharmaphorum
Mon, 10/28/24 - 10:19 am
Biogen
clinical trials
kidney disease
felzartamab
IgA nephropathy
Leqembi's vial design could result in hundreds of millions in annual Medicare waste: study
Fierce Pharma
Mon, 10/14/24 - 11:13 pm
Eisai
Biogen
Leqembi
Alzheimer's disease
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
Drugs.com
Sun, 10/13/24 - 11:30 am
Biogen
felzartamab
FDA
breakthrough therapy
kidney transplants
Biogen fills in some of the blanks on its trial of a high-dose version of Spinraza
Fierce Pharma
Wed, 10/9/24 - 09:52 am
Biogen
SMA
spinal muscular atrophy
Spinraza
Biogen scrapped stroke drug helps patients walk independently in Phase III trial
Clinical Trials Arena
Wed, 10/2/24 - 09:39 am
Biogen
stroke
clinical trials
Remedy Pharmaceuticals
CIRARA
Biogen cuts ties with Sage on failed tremor drug
First Word Pharma
Thu, 09/26/24 - 11:03 am
Biogen
SAGE Therapeutics
SAGE-324
essential tremor
City of Baltimore sues Biogen over allegedly paying PBMs to stave off Tecfidera generic competition
Medical Marketing and Media
Wed, 09/25/24 - 10:19 pm
Biogen
Baltimore
legal
PBMs
generics
competition
MS
Tecfidera
UCB, Biogen lupus drug scores in phase 3 trial
Pharmaphorum
Tue, 09/24/24 - 11:37 am
UCB Pharma
Biogen
systemic lupus erythematosus
clinical trials
dapirolizumab pegol
Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win
Fierce Pharma
Wed, 09/4/24 - 10:49 pm
Biogen
Spinraza
SMA
spinal muscular atrophy

Pages